RNA-focused digital therapeutics firm Flamingo Therapeutics added a brand new member to its board of administrators, Dr. Ezra Cohen.
Flamingo produces RNA therapies for oncology and is backed by traders corresponding to Andera Companions, Bpifrance Giant Enterprise, Perceptive Advisors, Sphera and VIB.
Dr. Cohen has a historical past within the improvement of prescribed drugs, particularly head and neck cancers.
“The science and crew at Flamingo are very spectacular, and I’m excited to affix the board following the current initiation of a number of necessary oncology medical research. I imagine that Flamingo is uniquely positioned to enhance the pinnacle and neck remedy panorama with its RNA-targeting strategy, and I sit up for working with the crew to ship new therapeutic choices for sufferers,” Dr. Cohen mentioned in a press release.
Life sciences software program firm Synthace introduced the appointment of Willem Baralt as its new chairman of the board. Baralt joined the corporate in February.
Synthace helps R&D scientists by means of automation throughout varied levels, together with experimental design, simulations and the creation of complete digital information.
Baralt has served on a number of boards of healthcare and charitable organizations. Most just lately, he served at transportable dialysis machine maker Quanta Dialysis Technologies, which secured $245 million in Series D funding in 2021.
“I’m really honored to affix the Synthace crew at this cut-off date as it’s trying to remodel the life sciences R&D panorama. With its digital experimentation platform, Synthace empowers scientists to design and execute experiments that have been beforehand unattainable. Synthace’s expertise is essential to enabling the R&D lab of the long run, permitting its prospects to make new therapies whereas reaching radical time and price financial savings,” Mr. Baralt mentioned in a press release.
